Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOVIT-ARDS high-dose intravenous vitamin C in septic ARDS
2024-516394-78-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sepsis and acute respiratory distress syndrome (ARDS) comparing High-dose intravenous sodium ascorbate with Placebo (sodium chloride) (2 arms). Primary endpoint: Death or persistent organ dysfunction at 28 days. Planned start Nov 2024; status: authorised.
02
Drugs
sodium ascorbate
03
Conditions
sepsisacute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2024-516394-78-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516394-78-00.